ArticleCureus2025
Acute Pleuropericardial Syndrome Following Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleuropericardial syndrome, a rare inflammatory complication associated with messenger ribonucleic acid (mRNA) COVID-19 vaccination, is predominantly reported in younger men but may also occur in older adults following booster doses, as illustrated by this case of a 68-year-old woman. Three days after receiving her third (booster) dose, she presented with flu-like symptoms, palpitations, and progressively worsening dyspnea. Diagnostic imaging revealed a large pericardial effusion and a moderate pleural effusion. Emergent pericardiocentesis was performed, draining 850 mL of serosanguinous fluid. Subsequent anti-inflammatory therapy led to complete resolution of symptoms, with no recurrence over a 15-month follow-up period. This presentation is likely driven by immune-mediated serosal inflammation, potentially triggered by the activation of innate immune pathways or molecular mimicry following mRNA vaccination. This case underscores the importance of prompt recognition and thorough differential diagnosis, even in atypical patient demographics such as older women postbooster vaccination. It further highlights the need for systematic reporting of such adverse events to pharmacovigilance systems, thereby supporting ongoing vaccine safety monitoring and informing future booster strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.